Plazomicin

Last updated

Plazomicin
Plazomicin structure.svg
Clinical data
Pronunciationpla" zoe mye' sin
Trade names Zemdri
Other namesACHN-490,
6'-(Hydroxylethyl)-1-(HABA)-sisomicin
AHFS/Drugs.com Monograph
MedlinePlus a618037
License data
Routes of
administration
Intravenous
Drug class Aminoglycoside
ATC code
Legal status
Legal status
Identifiers
  • (2S)-4-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
Formula C25H48N6O10
Molar mass 592.691 g·mol−1
3D model (JSmol)
  • CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(=CC[C@H]3N)CNCCO)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O
  • InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1
  • Key:IYDYFVUFSPQPPV-PEXOCOHZSA-N

Plazomicin, sold under the brand name Zemdri, is an aminoglycoside antibiotic used to treat complicated urinary tract infections. [2] As of 2019 it is recommended only for those in whom alternatives are not an option. [2] It is given by injection into a vein. [2]

Contents

Common side effects include kidney problems, diarrhea, nausea, and blood pressure changes. [2] Other severe side effects include hearing loss, Clostridioides difficile-associated diarrhea, anaphylaxis, and muscle weakness. [2] Use during pregnancy may harm the baby. [2] Plazomicin works by decreasing the ability of bacteria to make protein. [2]

Plazomicin was approved for medical use in the United States in 2018. [3] [4] It is on the World Health Organization's List of Essential Medicines. [5]

Medical uses

Plazomicin is approved by the U.S. Food and Drug Administration (FDA) for adults with complicated urinary tract infections, including pyelonephritis, caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , or Enterobacter cloacae , in patients who have limited or no alternative treatment options. Zemdri is an intravenous infusion, administered once daily. [6] [7] [8] [9] The FDA declined approval for treating bloodstream infections due to lack of demonstrated effectiveness. [3] The lack of demonstrated effectiveness was not so much about the antibiotic itself being ineffective so much as the low enrollment rate for the study. Studies using mouse models however, showed a high survival rate. [10]

Plazomicin has been reported to demonstrate in vitro synergistic activity when combined with daptomycin or ceftobiprole versus methicillin-resistant Staphylococcus aureus, vancomycin-resistant S. aureus and against Pseudomonas aeruginosa when combined with cefepime, doripenem, imipenem or piperacillin/tazobactam. [11] It also demonstrates potent in vitro activity versus carbapenem-resistant Acinetobacter baumannii . [12] Plazomicin was found to be noninferior to meropenem. [13] [14]

History

The drug was developed by the biotech company Achaogen. In 2012, the U.S. Food and Drug Administration granted fast track designation for the development and regulatory review of plazomicin. [15] The FDA approved plazomicin for adults with complicated UTIs and limited or no alternative treatment options in 2018. [6] Achaogen was unable to find a robust market for the drug, and declared bankruptcy a few months later. [16] As part of the bankruptcy process, the rights to plazomicin were sold to Cipla USA, who currently markets ZEMDRI. [17] There is no generic plazomicin currently available in the US market. [18]

Synthesis

It is derived from sisomicin by appending a hydroxy-aminobutyric acid substituent at position 1 and a hydroxyethyl substituent at position 6'. [19] [11] The latter makes it impervious to acetylation (deactivation) by Aminoglycoside Acetyltransferase 6'-N- Type Ib (AAC(6')-Ib), the most prevalent AAC enzyme. [20]

Names

Plazomicin is the international nonproprietary name (INN). [21]

Related Research Articles

<span class="mw-page-title-main">Amoxicillin/clavulanic acid</span> Combination antibiotic medication

Amoxicillin/clavulanic acid, also known as co-amoxiclav or amox-clav, sold under the brand name Augmentin, among others, is an antibiotic medication used for the treatment of a number of bacterial infections. It is a combination consisting of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. It is specifically used for otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is taken by mouth or by injection into a vein.

<span class="mw-page-title-main">Meropenem</span> Broad-spectrum antibiotic

Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.

<span class="mw-page-title-main">Cefixime</span> A third generation cephalosporin antibiotic

Cefixime, sold under the brand name Suprax among others, is an antibiotic medication used to treat a number of bacterial infections. These infections include otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease. For gonorrhea typically only one dose is required. In the United States it is a second-line treatment to ceftriaxone for gonorrhea. It is taken by mouth.

<span class="mw-page-title-main">Tigecycline</span> Chemical compound

Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline class drug that is administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.

<span class="mw-page-title-main">Carbapenem</span> Class of highly effective antibiotic agents

Carbapenems are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins. Furthermore, carbapenems are typically unaffected by emerging antibiotic resistance, even to other beta-lactams.

<span class="mw-page-title-main">Amikacin</span> Antibiotic medication

Amikacin is an antibiotic medication used for a number of bacterial infections. This includes joint infections, intra-abdominal infections, meningitis, pneumonia, sepsis, and urinary tract infections. It is also used for the treatment of multidrug-resistant tuberculosis. It is used by injection into a vein using an IV or into a muscle.

A drug of last resort (DoLR), also known as a heroic dose, is a pharmaceutical drug which is tried after all other drug options have failed to produce an adequate response in the patient. Drug resistance, such as antimicrobial resistance or antineoplastic resistance, may make the first-line drug ineffective, especially in case of multidrug-resistant pathogens and tumors. Such an alternative may be outside of extant regulatory requirements or medical best practices, in which case it may be viewed as salvage therapy.

<span class="mw-page-title-main">Cinoxacin</span> Chemical compound

Cinoxacin is a quinolone antibiotic that has been discontinued in the U.K. as well the United States, both as a branded drug or a generic. The marketing authorization of cinoxacin has been suspended throughout the EU.

<i>Acinetobacter baumannii</i> Species of bacterium

Acinetobacter baumannii is a typically short, almost round, rod-shaped (coccobacillus) Gram-negative bacterium. It is named after the bacteriologist Paul Baumann. It can be an opportunistic pathogen in humans, affecting people with compromised immune systems, and is becoming increasingly important as a hospital-derived (nosocomial) infection. While other species of the genus Acinetobacter are often found in soil samples, it is almost exclusively isolated from hospital environments. Although occasionally it has been found in environmental soil and water samples, its natural habitat is still not known.

<span class="mw-page-title-main">Fosfomycin</span> Chemical compound

Fosfomycin, sold under the brand name Monurol among others, is an antibiotic primarily used to treat lower urinary tract infections. It is not indicated for kidney infections. Occasionally it is used for prostate infections. It is generally taken by mouth.

<span class="mw-page-title-main">Nathaniel David</span> American scientist and entrepreneur

Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx, Achaogen, Kythera Biopharmaceuticals, Sapphire Energy and Unity Biotechnology. These companies have collectively raised more than $1.5 billion in financing.

<span class="mw-page-title-main">Omadacycline</span> Chemical compound

Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.

<span class="mw-page-title-main">Eravacycline</span> Chemical compound

Eravacycline is a synthetic halogenated tetracycline class antibiotic by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) were recently completed with mixed results. Eravacycline was granted fast track designation by the FDA and is currently available in USA.

<span class="mw-page-title-main">Ceftolozane/tazobactam</span> Antibiotic

Ceftolozane/tazobactam, sold under the brand name Zerbaxa, is a fixed-dose combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia.

<span class="mw-page-title-main">Ceftazidime/avibactam</span> Combination antibiotic medication

Ceftazidime/avibactam, sold under the brand name Avycaz among others, is a fixed-dose combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. It is used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia. It is only recommended when other options are not appropriate. It is given by infusion into a vein.

<span class="mw-page-title-main">Vaborbactam</span> Chemical compound

Vaborbactam (INN) is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.

Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It contains meropenem, a beta-lactam antibiotic, and vaborbactam, a beta-lactamase inhibitor. It is given by injection into a vein.

<span class="mw-page-title-main">Cefiderocol</span> Antibiotic

Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. It is given by injection into a vein.

<span class="mw-page-title-main">Relebactam</span> Chemical compound

Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio).

Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections. It is administered via intravenous injection.

References

  1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  2. 1 2 3 4 5 6 7 "Plazomicin Sulfate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 August 2020. Retrieved 10 October 2019.
  3. 1 2 "FDA Approved Drug Products: Zemdri". U.S. Food and Drug Administration . Archived from the original on 28 November 2020. Retrieved 28 June 2018.
  4. "Drug Approval Package: Zemdri (plazomicin)". U.S. Food and Drug Administration . 5 July 2018. Archived from the original on 28 November 2020. Retrieved 25 December 2019.
  5. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. 1 2 "Zemdri (plazomicin)- plazomicin injection". DailyMed. 30 July 2020. Archived from the original on 22 February 2021. Retrieved 11 October 2020.
  7. "plazomicin (Rx)". Medscape . Archived from the original on 28 November 2020. Retrieved 14 September 2019.
  8. Brown T (3 May 2018). "FDA Panel Recommends Plazomicin for cUTI but Not BSI". Medscape. Archived from the original on 25 November 2020. Retrieved 14 September 2019.
  9. "BioCentury - FDA approves plazomicin for cUTI, but not blood infections". www.biocentury.com. Archived from the original on 14 August 2020. Retrieved 28 June 2018.
  10. "Plazomicin". fda.gov. Antimicrobial Drugs Advisory Committee. 2 May 2018. Archived from the original on 27 December 2020.
  11. 1 2 Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, et al. (April 2012). "Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin". Expert Review of Anti-Infective Therapy. 10 (4): 459–473. doi:10.1586/eri.12.25. PMID   22512755. S2CID   31496981.
  12. García-Salguero C, Rodríguez-Avial I, Picazo JJ, et al. (October 2015). "Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?". Antimicrob Agents Chemother. 59 (10): 5959–66. doi:10.1128/AAC.00873-15. PMC   4576036 . PMID   26169398.
  13. Clinical trial number NCT02486627 for "A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (EPIC)" at ClinicalTrials.gov
  14. Wagenlehner FM, Cloutier DJ, Komirenko AS, et al. (21 February 2019). "Once-Daily Plazomicin for Complicated Urinary Tract Infections". New England Journal of Medicine. 380 (8): 729–740. doi: 10.1056/nejmoa1801467 . ISSN   0028-4793. PMID   30786187.
  15. "Achaogen Announces Plazomicin Granted QIDP Designation by FDA" (Press release). Achaogen, Inc. 8 January 2015. Archived from the original on 28 April 2016. Retrieved 27 April 2016 via GlobeNewswire.
  16. Jacobs A (25 December 2019). "Crisis Looms in Antibiotics as Drug Makers Go Bankrupt". The New York Times . Archived from the original on 1 February 2021. Retrieved 12 July 2024.
  17. "Cipla acquires plazomicin - July 2019". Cipla.com (Press release). Retrieved 12 September 2024.{{cite press release}}: CS1 maint: url-status (link)
  18. "Generic Zemdri Availability". Drugs.com. Archived from the original on 6 August 2020. Retrieved 26 December 2019.
  19. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, et al. (November 2010). "Synthesis and spectrum of the neoglycoside ACHN-490". Antimicrobial Agents and Chemotherapy. 54 (11): 4636–4642. doi:10.1128/AAC.00572-10. PMC   2976124 . PMID   20805391.
  20. Cox G, Ejim L, Stogios PJ, Koteva K, Bordeleau E, Evdokimova E, et al. (June 2018). "Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes". ACS Infectious Diseases. 4 (6): 980–987. doi:10.1021/acsinfecdis.8b00001. PMC   6167752 . PMID   29634241.
  21. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 68". WHO Drug Information. 26 (3). World Health Organization: 314. September 2012. Archived from the original on 2 October 2014. Retrieved 27 April 2016.

Further reading